The transition to generic alternatives for diabetes and autoimmune treatments is expected to save health plans billions, yet the shift introduces significant supply chain variables. While the FDA requires bioequivalence, manufacturers often utilize different facilities, inactive ingredients, and production processes that can alter a drug's performance. Parekh argues that federal oversight remains limited, noting that the FDA tests only a fraction of products on the market, leaving a gap that private litigation and independent laboratory testing must fill.

Wisner Baum is currently collaborating with pharmacokinetic experts and epidemiologists to analyze suspected failures in potency or purity. By utilizing legal discovery, the firm aims to access manufacturing records and internal data that are otherwise shielded from public view. Parekh stresses that patients are rarely informed when their pharmacy switches generic suppliers, a lack of transparency that complicates the identification of adverse effects or treatment failures. The firm is now soliciting information from patients and health plans regarding potential quality issues to determine whether observed health declines are linked to specific manufacturing defects.